Executive summary
U.S. Patent 6,277,384 claims oral opioid-agonist/opioid-antagonist combination drug products and methods intended to preserve analgesia while creating an aversive effect specifically in physically dependent humans at doses equal to or above the therapeutically effective dose. Claim scope is built around (1) an oral dosage form, (2) defined antagonist-to-agonist ratio ranges, (3) specific antagonist/agonist pairings (with naltrexone and hydrocodone as an anchor), (4) optional inclusion of non-opioid adjuncts, and (5) optional sustained-release carriers. The estate is centered on combination-content and functional performance criteria (aversive in dependent subjects; no increase in analgesic efficacy versus the same agonist dose absent antagonist).
Because you provided only the claim set and not the full patent text (specification, prosecution history, and bibliographic details like priority/filing/grant/maintenance status), a complete, defensible landscape analysis across specific related patents and legal status cannot be produced. The analysis below is limited to claim-driven scope mapping and the resulting infringement and freedom-to-operate risk framework that can be derived strictly from the provided claims.
What is U.S. Patent 6,277,384 claiming: oral opioid agonist-opioid antagonist aversive combination products?
Core claim thesis (independent claims 1, 26, 50)
-
Claim 1 (product): An oral dosage form containing:
- an orally therapeutically effective dose of an opioid agonist
- an opioid antagonist
- with an antagonist:agonist ratio that yields:
- analgesic efficacy when taken orally
- but is:
- aversive in physically dependent human subjects at the same dose or higher than the therapeutically effective dose
- while maintaining analgesic effect but does not increase analgesic efficacy of the opioid agonist versus the same therapeutic dose of opioid analgesic in patients without the opioid antagonist.
-
Claim 26 (method): A method of preventing oral abuse by preparing an oral dosage form meeting the same functional criteria and ratio logic.
-
Claim 50 (product, broader functional last clause): Similar to claim 1, but the analgesia functional requirement is expressed as “maintains or decreases analgesic efficacy” (instead of the “does not increase” formulation).
Key claim construction levers
- Route requirement
- “oral dosage form” is explicit for both products and preparation method.
- Functional criteria
- “aversive in physically dependent human subjects” at a defined dosing context.
- analgesia preservation for non-dependent patients and prohibition on analgesia increase (or permission to decrease in claim 50).
- Ratio requirement
- The independent claims require a ratio “that provides” the specified performance profile.
- Defined content scope via dependent claims
- Dependent claims narrow or specify:
- antagonist identity
- agonist identity
- antagonist-to-agonist ratio ranges
- optional inclusion of other drug classes
- optional sustained-release carrier.
What is the scope of claim 1 product protection: how does “therapeutically effective dose” and “aversive in dependent subjects” limit coverage?
Answer
Claim 1 covers any oral opioid agonist/opioid antagonist oral combination that meets the specified analgesia and aversion/analgesia performance profile relative to the same agonist dose administered without the antagonist, and that uses a ratio yielding those outcomes.
Functional language creates a performance-based infringement hook
- For aversiveness: the claim requires that the formulation is “aversive in physically dependent human subjects” at the same or higher dose than the therapeutically effective dose.
- For analgesia:
- Claim 1: maintains analgesic effect but does not increase analgesic efficacy of the agonist versus the same therapeutic dose of opioid analgesic without antagonist.
- Claim 50: “maintains or decreases” analgesic efficacy versus the same therapeutic dose of opioid analgesic without antagonist.
Practical implication
- A generic or reformulated oral opioid-antagonist product does not avoid claim 1 by preserving analgesia alone; it must also fail the “aversive in dependent subjects” criterion or otherwise fail the required comparative analgesia constraint.
Which antagonist and agonist combinations are explicitly covered (naltrexone anchor, opioid agonist set)?
Antagonist options (dependent claims 9 and 10)
- Claim 9 limits antagonist to one or more of:
- naltrexone
- naloxone
- nalmephene
- cyclazocine
- levallorphan
- mixtures
- Claim 10 specifies: antagonist is naltrexone.
Agonist options (dependent claim 6)
- Claim 6 lists opioid agonist options:
- morphine
- hydromorphone
- hydrocodone
- oxycodone
- codeine
- levorphanol
- meperidine
- methadone
- mixtures
Naltrexone pairing emphasis
- Claim 3/4: hydrocodone + naltrexone ratio ranges.
- Claim 12 onward: multiple naltrexone/agonist ratio ranges for oxycodone, codeine, hydromorphone, levorphanol, meperidine, methadone, morphine (and a further repetition in claim 19).
Coverage consequence
- At minimum, the dependent claim set indicates the patent’s commercial targeting around antagonist/agonist pair ratios that can plausibly be tuned to deliver analgesia in non-dependent patients while creating dependent-subject aversion.
What patents protect hydrocodone/naltrexone oral abuse-deterrent combinations in defined ratio windows?
Answer
Within claim logic, hydrocodone/naltrexone is protected where the ratio of naltrexone to hydrocodone falls inside the claimed ranges.
Hydrocodone/naltrexone ratio ranges
- Claim 4: naltrexone:hydrocodone 0.03:1 to 0.27:1
- Claim 5: naltrexone:hydrocodone 0.05:1 to 0.20:1
- Claim 2 adds a dependent functional marker:
- aversive experience in physically dependent addicts taking about 2–3 times the therapeutically effective dose
Scope note
- Claim 4 and claim 5 are dependent on claim 3’s pairing (hydrocodone + naltrexone), so a product with those ingredients and in-range ratios would map directly to those dependent claim limitations, if the independent functional criteria are also met.
Which additional ratio ranges are claimed for naltrexone with other opioid agonists?
Answer
The patent specifies multiple naltrexone:agonist windows, likely representing formulation dosing targets tied to dependent-subject aversion while keeping analgesia.
Naltrexone/oxycodone
- Claim 12: 0.037:1 to 0.296:1
- Claim 19: 0.056:1 to 0.222:1
Naltrexone/codeine
- Claim 13: 0.005:1 to 0.044:1
- Claim 20: 0.0083:1 to 0.033:1
Naltrexone/hydromorphone
- Claim 14: 0.148:1 to 1.185:1
- Claim 21: 0.222:1 to 0.889:1
Naltrexone/levorphanol
- Claim 15: 0.278:1 to 2.222:1
- Claim 22: 0.417:1 to 1.667:1
Naltrexone/meperidine
- Claim 16: 0.0037:1 to 0.0296:1
- Claim 23: 0.0056:1 to 0.022:1
Naltrexone/methadone
- Claim 17: 0.056:1 to 0.444:1
- Claim 24: 0.083:1 to 0.333:1
Naltrexone/morphine
- Claim 18: 0.018:1 to 0.148:1
- Claim 25: 0.028:1 to 0.111:1
How these ranges shape infringement analysis
- If an accused oral opioid-antagonist product matches the claimed antagonist/agonist pairing and ratio range, the remaining issue becomes whether it meets the independent functional criteria on aversiveness and analgesia performance in dependent vs non-dependent human patients at the same or higher dose than the therapeutically effective dose.
What formulations are protected beyond ratios: sustained-release carrier and non-opioid adjunct drugs?
Sustained-release carrier
- Claim 11 (product): further comprising a sustained release carrier which imparts sustained release properties to the opioid agonist.
- Claim 35 (method): sustained release carrier such that the dosage form is administrable on a twice-a-day or once-a-day basis.
Non-opioid adjunct drugs
- Claim 7 (product) and Claim 34 (method) add optional adjuncts:
- NSAID
- COX-2 inhibitor
- acetaminophen
- aspirin
- NMDA receptor antagonist
- a drug that blocks a major intracellular consequence of NMDA-receptor activation
- antitussive
- expectorant
- decongestant
- antihistamine
- mixtures
Scope consequence
- The patent covers the core opioid antagonism/agonism concept, and also supports broader claims that include adjunct symptom-modifying agents. This expands potential infringement surface to multi-ingredient oral analgesic or combination therapy products that still satisfy the independent aversion and analgesia constraints.
How broadly does claim 26 cover “preventing oral abuse” as a method claim?
Answer
Claim 26 protects preparing an oral opioid agonist/antagonist dosage form where the antagonist:agonist ratio provides analgesic efficacy orally yet is aversive in dependent subjects and does not increase analgesic efficacy in non-dependent patients without the antagonist.
Dependent claim coverage in method space
- Claim 27: aversive at ~2–3× therapeutically effective dose.
- Claim 28-30: hydrocodone+naltrexone and ratio windows.
- Claim 31: broad pairing selections between the agonist set and antagonist set.
- Claims 32-47: detailed naltrexone/agonist ratio windows corresponding to the product-dependent claims.
- Claim 34: adjunct drug inclusion.
- Claim 35: sustained-release dosing frequency.
Net effect
- Method infringement risk can attach to formulation development and manufacturing steps if the prepared product meets the claimed performance and ratio requirements, not only to product distribution.
What is the “analgesia” comparative standard: could a product with decreased efficacy avoid infringement?
Answer
- Claim 1 requires “maintains analgesic effect but does not increase analgesic efficacy” versus the same agonist dose without antagonist.
- Claim 50 allows “maintains or decreases” analgesic efficacy.
A product that decreases analgesic efficacy may still fall within claim 50, while claim 1 could be avoided depending on how “maintains” is interpreted relative to “decreases.” Since the independent language includes a comparative baseline without antagonist, the key is performance characterization in human subjects at the same therapeutic dose of opioid analgesic.
How does claim 2’s “2–3 times” aversion limitation affect scope and design-around?
Answer
Claim 2 is an additional dependent limitation: in physically dependent addicts taking about 2–3× the therapeutically effective dose, the antagonist amount included causes an aversive experience.
Implication
- A product could potentially match the ratio and ingredient identities yet not cause aversion at the “2–3×” dosing window. However, since claim 1 independently requires aversiveness at the same dose or higher than the therapeutically effective dose, the “2–3×” clause appears to sharpen evidence and scope for dependent claim 2 rather than define the only aversive condition.
What patent estate and Orange Book status can be concluded from U.S. 6,277,384 alone?
No definitive landscape statement can be produced from the claim text alone.
- Orange Book listings depend on the specific NDA/ANDA products and listed patents tied to those applications.
- A full “patent estate” assessment requires the patent’s publication data, priority/continuation chain, maintenance status, and identification of related patents by assignee and family members.
- Litigation and Paragraph IV challenge risk require Orange Book patent list mapping and court docket confirmation.
Because those inputs are not provided, a complete estate and litigation status analysis is not supportable within the constraints.
Where is the infringement risk highest based on claim structure: ratio windows + naltrexone/agonist identity + oral dosage + performance criteria?
Highest-risk product profiles (claim-aligned)
- Oral opioid analgesics using naltrexone (or other listed antagonists) combined with one of the listed opioid agonists.
- Formulations that set antagonist:agonist ratios within the claimed windows for the specific pairing.
- Products that generate:
- adequate analgesia in non-dependent patients
- and aversion in physically dependent subjects at the same or higher dosing level than the therapeutically effective dose.
Lower-risk design directions (claim-avoidance theory)
- Use opioid antagonists outside the specified antagonist set, or opioid agonists outside the specified agonist set, while still meeting the independent claim’s requirement set for the specific combination claims. (This does not eliminate risk under the independent claim, which recites antagonist/agonist generally, but it directly reduces coverage under the more specific dependent claims.)
- Use ratios outside the dependent claim windows. This does not automatically avoid claim 1 because claim 1 is not limited to the enumerated windows, but it can defeat dependent claim coverage if the accused ratio is outside the specific listed ranges.
Key takeaways
- U.S. 6,277,384 claims oral opioid agonist/opioid antagonist combination products and preparation methods defined by a ratio that produces oral analgesia while creating aversion in physically dependent subjects and preventing an increase in analgesic efficacy versus the same agonist dose without antagonist (claim 1) or allowing decrease (claim 50).
- The claim set strongly targets naltrexone paired with hydrocodone (with specific ratio ranges) and also enumerates multiple naltrexone/agonist ratio windows for oxycodone, codeine, hydromorphone, levorphanol, meperidine, methadone, and morphine.
- Scope expands through dependent claims for sustained-release carriers and optional non-opioid adjunct drugs (NSAIDs/COX-2 inhibitors/acetaminophen/aspirin and other classes listed).
- Practical infringement exposure is driven by (1) oral combination composition, (2) antagonist:agonist ratios, and (3) whether human subject performance matches the aversiveness and comparative analgesia constraints.
FAQs
-
Does U.S. 6,277,384 cover naloxone-based combinations with hydrocodone in oral dosage forms?
Yes, the antagonist set includes naloxone, and the product and method claims are written to cover oral opioid agonist/opioid antagonist combinations, with dependent claim pathways specifying pairing and ratios where applicable.
-
Is a sustained-release formulation required for infringement?
No. Sustained-release carrier appears only in dependent claim 11 (product) and dependent claim 35 (method). The independent claims do not require sustained release.
-
Can a formulation that decreases analgesia still infringe?
Claim 50 explicitly allows “maintains or decreases analgesic efficacy” relative to the same therapeutic dose of opioid analgesic without the antagonist.
-
What role do ratio ranges play if the formulation meets the functional criteria?
Dependent claim ratio ranges provide specific composition windows. The independent claims require a ratio that yields the functional performance, so ratio evidence remains central for both independent and dependent coverage.
-
Would adding an NSAID or acetaminophen create separate infringement exposure?
Adjunct inclusion is covered in dependent claims 7 (product) and 34 (method). It can increase claim coverage if the core opioid agonist/opioid antagonist ratio and performance requirements are met.
References
No sources cited.
